Cite
HARVARD Citation
van Vollenhoven, R. et al. (2018). Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. 392 (10155), pp. 1330-1339. [Online].